According to CoinMeta, on November 12, Xinnuowei announced that the company received a notice from the National Medical Products Administration approving the market launch of Yaxifuxu, a new class 1 drug for injection independently developed by the company. The approved indications for this drug are hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.